Literature DB >> 8494601

Distribution of pheophorbide A in normal tissues and in an experimental pancreatic cancer in rats.

M Aprahamian1, S Evrard, P Keller, M Tsuji, G Balboni, C Damgé, J Marescaux.   

Abstract

The in vivo administration and distribution of a potent new photosensitizer, pheophorbide A (PH-A), was investigated in rats. The spectral characteristics were determined. This hydrophobic compound was solubilized by an ethanol/phosphate-buffered saline (PBS) mixture (v/v) and sonicated immediately before i.v. administration. Tissue distribution and the affinity of PH-A for an acinar pancreatic tumor were determined in Lewis rats for up to 48 h after a single i.v. administration of 3 mg kg-1 body wt. Methanol-extracted PH-A was quantitatively determined by fluorescence spectrophotometry at 665.6 nm. The PH-A uptake pattern showed that the reticulo-endothelial system is the major target of PH-A, followed by the gut and then the lung and pancreas. PH-A concentrations in skin were very low. The presence of an enterohepatic cycle was suggested by the PH-A biliary output, intestinal uptake and blood concentrations. Tumor PH-A retention was longer than pancreatic retention. The ratio of tumoral to peri-tumoral pancreas PH-A was 6.7:1, 24 h after i.v. administration. With its similar tissue pattern, better absorption spectrum and lower skin toxicity, PH-A could be a more potent photosensitizer than hematoporphyrin derivatives.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494601

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  2 in total

1.  The growth pattern and microvasculature of pancreatic tumours induced with cultured carcinoma cells.

Authors:  K Mäkinen; S Loimas; P Nuutinen; M Eskelinen; E Alhava
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

2.  Selectivity of the photosensitiser Tookad for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model.

Authors:  F Borle; A Radu; C Fontolliet; H van den Bergh; P Monnier; G Wagnières
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.